143 related articles for article (PubMed ID: 18163186)
1. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
[TBL] [Abstract][Full Text] [Related]
2. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Mol Model; 2008 Nov; 14(11):1009-21. PubMed ID: 18642033
[TBL] [Abstract][Full Text] [Related]
3. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
4. Conformation depends on 4D-QSAR analysis using EC-GA method: pharmacophore identification and bioactivity prediction of TIBOs as non-nucleoside reverse transcriptase inhibitors.
Akyüz L; Sarıpınar E
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):776-91. PubMed ID: 22591319
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase.
Gupta SP; Garg R
J Enzyme Inhib; 1996 Aug; 11(1):23-32. PubMed ID: 9204393
[TBL] [Abstract][Full Text] [Related]
7. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
8. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs).
Barreca ML; Carotti A; Carrieri A; Chimirri A; Monforte AM; Calace MP; Rao A
Bioorg Med Chem; 1999 Nov; 7(11):2283-92. PubMed ID: 10632038
[TBL] [Abstract][Full Text] [Related]
9. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
[TBL] [Abstract][Full Text] [Related]
10. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
11. Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives.
Darnag R; Mostapha Mazouz EL; Schmitzer A; Villemin D; Jarid A; Cherqaoui D
Eur J Med Chem; 2010 Apr; 45(4):1590-7. PubMed ID: 20110136
[TBL] [Abstract][Full Text] [Related]
12. QSAR modeling with the electrotopological state: TIBO derivatives.
Huuskonen J
J Chem Inf Comput Sci; 2001; 41(2):425-9. PubMed ID: 11277732
[TBL] [Abstract][Full Text] [Related]
13. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
14. Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.
Freitas RF; Galembeck SE
J Phys Chem B; 2006 Oct; 110(42):21287-98. PubMed ID: 17048958
[TBL] [Abstract][Full Text] [Related]
15. A group center overlap based approach for "3D QSAR" studies on TIBO derivatives.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Chem; 2009 Apr; 30(6):922-33. PubMed ID: 18785154
[TBL] [Abstract][Full Text] [Related]
16. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
De Corte BL
J Med Chem; 2005 Mar; 48(6):1689-96. PubMed ID: 15771411
[No Abstract] [Full Text] [Related]
17. Structural flexibility of non-nucleoside HIV-1 reverse transcriptase inhibitor: 9-Cl TIBO as explained by potential energy surface and (13)C and (1)H NMR calculations, based on ab initio and density functional study.
Saen-Oon S; Hannongbua S; Wolschann P
J Chem Inf Comput Sci; 2003; 43(5):1412-22. PubMed ID: 14502474
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.
Hannongbua S; Pungpo P; Limtrakul J; Wolschann P
J Comput Aided Mol Des; 1999 Nov; 13(6):563-77. PubMed ID: 10584215
[TBL] [Abstract][Full Text] [Related]
19. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.
Smith RH; Jorgensen WL; Tirado-Rives J; Lamb ML; Janssen PA; Michejda CJ; Kroeger Smith MB
J Med Chem; 1998 Dec; 41(26):5272-86. PubMed ID: 9857095
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
